Literature DB >> 21671440

The use of medications with anticholinergic properties and risk factors for their use in hospitalised elderly patients.

Martin Wawruch1, Agata Macugova, Lenka Kostkova, Jan Luha, Andrej Dukat, Jan Murin, Veronika Drobna, Lynda Wilton, Magdalena Kuzelova.   

Abstract

PURPOSE: The aims of the present study were to evaluate the use of drugs with anticholinergic properties in elderly patients and to identify risk factors that increase the patient's chance of being given such medications.
METHODS: The study was performed on a sample of 1636 patients aged ≥65 years hospitalised during the period between 1 January 2008 and 31 December 2009 in three municipal hospitals. To evaluate the factors influencing the use of anticholinergic medications, we compared two groups-users and non-users of such drugs-in terms of sociodemographic and clinical characteristics as well as comorbid conditions. The most important risk factors were identified using the binary logistic regression model.
RESULTS: Hospitalisation led to a significant increase in the prevalence of anticholinergic medication users, when comparing their occurrence at the time of hospital admission and discharge (10.5% and 14.2%, respectively; p < 0.001). A significantly higher total number of prescribed drugs were found in the group of users compared with non-users, at both hospital admission (7.2 ± 3.5 vs 5.7 ± 3.1; p < 0.001) and discharge (8.7 ± 3.1 vs 7.5 ± 2.9; p < 0.001). Immobilisation, urinary incontinence and retention, constipation, gastroduodenal ulcer disease as well as neurologic and psychiatric comorbidities (depression, Parkinson's disease, epilepsy) appeared as the most important risk factors of using anticholinergic medications.
CONCLUSIONS: Physicians should be aware of the greater risk of adverse anticholinergic effects of drugs in certain therapeutic classes in the elderly. In patients with risk factors mentioned previously, special attention should be paid to active identification of anticholinergic effects of medications.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671440     DOI: 10.1002/pds.2169

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  18 in total

1.  Potentially inappropriate anticholinergic medication use in community-dwelling older adults: a national cross-sectional study.

Authors:  Nandita Kachru; Ryan M Carnahan; Michael L Johnson; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

2.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

3.  Association of Anticholinergic Drug Burden with Cognitive and Functional Decline Over Time in Older Inpatients: Results from the CRIME Project.

Authors:  Gloria Brombo; Lara Bianchi; Elisa Maietti; Francesca Malacarne; Andrea Corsonello; Antonio Cherubini; Carmelinda Ruggiero; Graziano Onder; Stefano Volpato
Journal:  Drugs Aging       Date:  2018-10       Impact factor: 3.923

4.  Chronic constipation: improved understanding offers a new therapeutic approach.

Authors:  Gareth J Sanger
Journal:  J Physiol       Date:  2016-08-01       Impact factor: 5.182

Review 5.  Different methods, different results--how do available methods link a patient's anticholinergic load with adverse outcomes?

Authors:  Tanja Mayer; Walter E Haefeli; Hanna M Seidling
Journal:  Eur J Clin Pharmacol       Date:  2015-09-08       Impact factor: 2.953

6.  Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study.

Authors:  Pasi Lampela; Piia Lavikainen; J Arturo Garcia-Horsman; J Simon Bell; Risto Huupponen; Sirpa Hartikainen
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

7.  Anticholinergic component of the Drug Burden Index and the Anticholinergic Drug Scale as measures of anticholinergic exposure in older people in New Zealand: a population-level study.

Authors:  Sujita W Narayan; Sarah N Hilmer; Simon Horsburgh; Prasad S Nishtala
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

8.  Quantifying cumulative anticholinergic and sedative drug load among US Medicare Beneficiaries.

Authors:  Shahar Shmuel; Virginia Pate; Marc J Pepin; Janine C Bailey; Laura C Hanson; Til Stürmer; Rebecca B Naumann; Yvonne M Golightly; Danijela Gnjidic; Jennifer L Lund
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-10-15       Impact factor: 2.890

Review 9.  Association between Anticholinergic Burden and Constipation: A Systematic Review.

Authors:  Héctor Rodríguez-Ramallo; Nerea Báez-Gutiérrez; Elena Prado-Mel; Eva Rocío Alfaro-Lara; Bernardo Santos-Ramos; Susana Sánchez-Fidalgo
Journal:  Healthcare (Basel)       Date:  2021-05-13

Review 10.  Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.

Authors:  Jie Dong; Yanhua Cui; Song Li; Weidong Le
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.